Endoscopic ultrasound-fine needle biopsies of pancreatic lesions: Prospective study of histology quality using Franseen needle.
Endosonography
Fine needle biopsy
Franseen needle
Histology
Pancreatic lesions
Journal
World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448
Informations de publication
Date de publication:
07 Oct 2020
07 Oct 2020
Historique:
received:
29
07
2020
revised:
21
08
2020
accepted:
15
09
2020
entrez:
22
10
2020
pubmed:
23
10
2020
medline:
15
5
2021
Statut:
ppublish
Résumé
The introduction of fine needle biopsies (FNB) to clinical practice presents a changing trend towards histology in the endoscopic ultrasound-guided tissue acquisition (EUS-TA). To evaluate the clinical performance of a new FNB needle, the 22-gauge (22G) Franseen needle, when sampling pancreatic solid lesions. Consecutive patients with an indication for EUS-TA for the assessment of pancreatic solid lesions were included in this prospective, single-center, single-arm trial. Each patient underwent a puncture of the lesion two times using the 22G Franseen needle and the obtained samples were directly placed into formalin for histological analysis. The primary study endpoint was the rate of high-quality obtained specimen. Secondary endpoints included the length and diameter of the core specimen, the diagnostic accuracy and the complication rate. From June 2017 to December 2018, forty patients with pancreatic solid lesions (22 females; mean age 67.2 years) were enrolled. Tissue acquisition was achieved in all cases. High-quality histology, rated with Payne score 3, was obtained in 37/40 cases (92.5%) after two needle passes. The mean size of the acquired histological core tissue was 1.54 mm × 0.39 mm. The diagnostic accuracy for the correct diagnosis was 85% (34/40). Only one adverse event was occurred, consisting of a self-limiting bleeding in the puncture site. The 22G Franseen needle achieved according to our standardized protocol a high rate of histological core procurement, and a high diagnostic accuracy, with one minor adverse event reported.
Sections du résumé
BACKGROUND
BACKGROUND
The introduction of fine needle biopsies (FNB) to clinical practice presents a changing trend towards histology in the endoscopic ultrasound-guided tissue acquisition (EUS-TA).
AIM
OBJECTIVE
To evaluate the clinical performance of a new FNB needle, the 22-gauge (22G) Franseen needle, when sampling pancreatic solid lesions.
METHODS
METHODS
Consecutive patients with an indication for EUS-TA for the assessment of pancreatic solid lesions were included in this prospective, single-center, single-arm trial. Each patient underwent a puncture of the lesion two times using the 22G Franseen needle and the obtained samples were directly placed into formalin for histological analysis. The primary study endpoint was the rate of high-quality obtained specimen. Secondary endpoints included the length and diameter of the core specimen, the diagnostic accuracy and the complication rate.
RESULTS
RESULTS
From June 2017 to December 2018, forty patients with pancreatic solid lesions (22 females; mean age 67.2 years) were enrolled. Tissue acquisition was achieved in all cases. High-quality histology, rated with Payne score 3, was obtained in 37/40 cases (92.5%) after two needle passes. The mean size of the acquired histological core tissue was 1.54 mm × 0.39 mm. The diagnostic accuracy for the correct diagnosis was 85% (34/40). Only one adverse event was occurred, consisting of a self-limiting bleeding in the puncture site.
CONCLUSION
CONCLUSIONS
The 22G Franseen needle achieved according to our standardized protocol a high rate of histological core procurement, and a high diagnostic accuracy, with one minor adverse event reported.
Identifiants
pubmed: 33088162
doi: 10.3748/wjg.v26.i37.5693
pmc: PMC7545386
doi:
Types de publication
Clinical Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
5693-5704Informations de copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: Division of Endoscopy took grant from Boston Scientific Medizintechnik GmbH, outside the submitted work.
Références
Gastrointest Endosc. 2001 Apr;53(4):485-91
pubmed: 11275890
Dig Endosc. 2019 Mar;31(2):197-202
pubmed: 30256458
Dig Dis Sci. 2020 Apr;65(4):1155-1163
pubmed: 31531819
Endosc Ultrasound. 2019 Mar-Apr;8(2):99-104
pubmed: 29623911
Diagn Cytopathol. 2020 Mar;48(3):197-202
pubmed: 31850666
Gastrointest Endosc. 2014 Dec;80(6):1056-63
pubmed: 24973173
Endosc Ultrasound. 2018 Sep-Oct;7(5):329-334
pubmed: 28836520
Can J Gastroenterol Hepatol. 2019 Feb 3;2019:8581743
pubmed: 30854353
Cytopathology. 2011 Jun;22(3):174-8
pubmed: 20482717
Endosc Int Open. 2019 Oct;7(10):E1221-E1230
pubmed: 31579703
Endosc Ultrasound. 2019 Nov-Dec;8(6):412-417
pubmed: 31417069
Clin Gastroenterol Hepatol. 2018 Mar;16(3):318-327
pubmed: 29074447
Endosc Ultrasound. 2019 Jan-Feb;8(1):50-57
pubmed: 29786033
Clin Endosc. 2018 Nov;51(6):576-583
pubmed: 30001616
Endosc Ultrasound. 2019 Sep-Oct;8(5):321-328
pubmed: 30880724
Endoscopy. 2017 Oct;49(10):989-1006
pubmed: 28898917
Dig Endosc. 2017 May;29(3):338-346
pubmed: 27878861
Endosc Int Open. 2019 Feb;7(2):E189-E194
pubmed: 30705952
J Gastroenterol Hepatol. 2014 Apr;29(4):697-705
pubmed: 24783248
Endosc Int Open. 2019 Aug;7(8):E955-E963
pubmed: 31367675
Endosc Int Open. 2019 Nov;7(11):E1327-E1332
pubmed: 31673602
Cytopathology. 2013 Jun;24(3):159-71
pubmed: 23711182
Endosc Ultrasound. 2019 Nov-Dec;8(6):382-391
pubmed: 31249163
Gut. 2018 Dec;67(12):2081-2084
pubmed: 28988195
Gastrointest Endosc. 2018 Feb;87(2):495-500
pubmed: 28882575
PLoS One. 2016 Sep 22;11(9):e0163056
pubmed: 27657529
Gastrointest Endosc. 2018 Jun;87(6):1432-1438
pubmed: 29305893
Endoscopy. 2016 Apr;48(4):339-49
pubmed: 26561917
Ann Gastroenterol. 2018 Nov-Dec;31(6):742-746
pubmed: 30386126
Gastrointest Endosc. 2012 Feb;75(2):319-31
pubmed: 22248600
Diagn Cytopathol. 2009 Jan;37(1):21-9
pubmed: 18973122